How Much Weight Can You Lose on Semaglutide? What Clinical Trials Show

If you are considering a GLP-1 medication for weight management, one of the first questions you probably have is: how much weight semaglutide helps you lose? It is a reasonable question, and the clinical research offers a useful starting point. But the honest answer is more nuanced than any single number, and understanding the full picture will help you approach treatment with realistic expectations and stay motivated through the process.

This article reviews what published clinical trials have found about semaglutide and weight loss, the typical timeline for results, and the factors that shape individual outcomes.

*Compounded semaglutide is not FDA-approved. This article discusses findings from clinical research on semaglutide and is for educational purposes only. It does not constitute medical advice. Individual results vary. Consult your licensed healthcare provider before starting any medication.*

---

What the Clinical Research Shows

The most comprehensive data on semaglutide for weight management comes from the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program, a series of large randomized controlled trials published between 2021 and 2023.

The STEP 1 Trial: The Landmark Study

The STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related health condition. Participants received either subcutaneous semaglutide at 2.4 mg weekly or a placebo, combined with lifestyle intervention (diet and physical activity counseling) over 68 weeks.

Key findings at 68 weeks:

• Participants in the semaglutide group lost an average of 14.9% of their body weight
• Participants in the placebo group lost an average of 2.4% of their body weight
• 86.4% of those on semaglutide achieved at least 5% weight loss
• 69.1% achieved at least 10% weight loss
• 50.5% achieved at least 15% weight loss

In practical terms, for a person weighing 220 pounds, 15% body weight loss corresponds to approximately 33 pounds.

Important context: These results were observed in a controlled clinical trial using FDA-approved semaglutide 2.4 mg, combined with structured lifestyle support. Compounded semaglutide is not the same product, is not FDA-approved, and these clinical outcomes cannot be assumed to apply to compounded formulations.

The STEP 5 Trial: Two-Year Data

For anyone concerned about whether results hold up over time, the STEP 5 trial followed participants for two years. Results published in Nature Medicine in 2022 showed that participants maintained substantial weight loss through the full 104 weeks, with a mean reduction of 15.2% of body weight in the semaglutide group compared to 2.6% in the placebo group.

Two-year data suggests that continued treatment is associated with sustained weight reduction, rather than a short-term effect that reverses quickly.

What Happens If You Stop?

A critical finding from the STEP 1 extension study, published in Diabetes, Obesity and Metabolism in 2022, addressed weight regain after stopping semaglutide. One year after discontinuing treatment, participants had regained approximately two-thirds of the weight they had lost during the trial. This underscores that GLP-1 medications work while you take them, and sustainable lifestyle changes remain essential for long-term success.

---

*Adherence to your treatment plan, including regular provider check-ins and lifestyle modifications, is one of the strongest predictors of results.*

---

The Typical Weight Loss Timeline

Weight loss on semaglutide is gradual and progressive. The clinical data shows a predictable general pattern, though individual variation is significant.

Weeks 1 to 4: Early Adjustment

Most people notice some reduction in appetite during the first few weeks as the medication begins affecting hunger signals. Actual weight loss in this phase is typically modest. Your body is also adjusting to the medication, which means this is often when side effects like nausea are most noticeable. The standard approach is to start at a low dose and increase slowly, which limits side effects while allowing your body to adapt.

Do not measure success in weeks 1 to 4 by the number on the scale. Setting expectations for this period appropriately prevents early discouragement.

Months 2 to 4: Steady Progress

As you approach your maintenance dose, most people begin to see more consistent weight loss. Appetite suppression tends to become more noticeable, meal sizes naturally decrease, and the cumulative effects on eating behavior become more apparent. This is typically when most patients start seeing results they can feel.

Months 4 to 12: The Core Weight Loss Phase

The bulk of weight loss in the STEP trials occurred between months 4 and 12. This is the period during which the medication is working at or near full therapeutic effect, and lifestyle habits built during the earlier months pay dividends. Progress is rarely linear. You may have weeks of faster loss, weeks of slower loss, and periods that feel like plateaus.

Beyond 12 Months: Maintenance and Stabilization

After approximately 12 to 16 months, weight loss typically begins to slow as the body reaches a new equilibrium. This is a normal physiological response. The STEP 5 data suggests that weight can be maintained with continued treatment, but the rate of ongoing loss generally slows compared to the first year.

---

Factors That Affect Your Individual Results

No two people are the same, and published averages reflect outcomes across diverse populations. Several factors meaningfully shape individual results.

Starting Weight and BMI

People with higher starting body weights often see larger absolute weight loss in pounds, even when the percentage is similar. Someone starting at 300 pounds and achieving 15% body weight reduction loses 45 pounds. Someone starting at 180 pounds achieving the same percentage loses 27 pounds. Both are meaningful results.

Dose and Duration

Clinical data is dose-dependent. The 2.4 mg weekly dose used in the STEP 1 trial produced significantly greater weight loss than lower doses studied in earlier trials. Your provider determines your dose and escalation schedule based on your individual health profile and tolerability. Staying on the prescribed dose and schedule is important for achieving the full therapeutic effect.

Diet Quality

GLP-1 medications reduce appetite but do not control what you eat. The combination of reduced hunger and intentional food choices consistently outperforms medication alone. Focusing on protein-rich meals, limiting processed foods, and eating mindfully amplifies results.

Physical Activity

Exercise supports weight loss and is particularly important for preserving muscle mass during weight reduction. The STEP trials included structured lifestyle counseling alongside medication. Participants who maintained regular physical activity throughout treatment preserved lean muscle while losing fat.

Individual Biology

Genetics, hormonal factors, metabolic rate, gut microbiome composition, and other biological variables all influence how an individual responds to semaglutide. Some people are robust responders who see rapid, substantial results. Others see more modest outcomes. Both are real outcomes for real patients.

Adherence

Consistent adherence to the medication schedule, follow-up with your provider, and commitment to the lifestyle components of your treatment plan are among the strongest predictors of results. Missing doses, discontinuing early, or neglecting dietary changes substantially limits outcomes.

---

Setting Realistic Expectations

Understanding what "average" means in clinical trials helps you interpret published data appropriately.

When a study reports a mean weight loss of 14.9%, that number is the average across all participants, including those who responded strongly and those who responded modestly. Roughly half of participants lost more than that average, and roughly half lost less. About 50% of STEP 1 participants achieved at least 15% body weight loss, while some achieved more than 20% and others achieved less than 5%.

There is no reliable way to predict in advance which category you will fall into. The more useful frame is: semaglutide, when taken as prescribed in combination with a healthy diet and regular movement, is associated with clinically meaningful weight loss in the majority of people who use it. Expecting a specific number before you start is less useful than committing to the process and evaluating your response over time.

Your healthcare provider is the right person to assess whether your results are on track and whether any adjustments to your plan make sense.

---

The Role of Diet and Exercise

GLP-1 medications work best as part of a comprehensive approach to weight management. The clinical evidence consistently shows that medication combined with lifestyle modification outperforms medication alone.

On the practical side, reduced appetite from semaglutide creates an opportunity to build better eating habits. When you are less hungry, it becomes easier to focus on nutrition quality rather than just caloric intake. Prioritizing protein helps preserve lean muscle mass. Vegetables, fiber-rich foods, and adequate hydration all support the process.

Exercise plays a dual role: it contributes to the caloric deficit that drives weight loss, and it counteracts the muscle loss that can accompany significant weight reduction. Strength training in particular is valuable during a period of substantial weight loss.

The goal is not just a lower number on the scale but improved metabolic health, preserved muscle, and habits that support long-term wellness.

---

Frequently Asked Questions

How quickly will I see results on semaglutide? Most people notice some reduction in appetite within the first few weeks. Meaningful weight loss on the scale typically becomes apparent around months 2 to 4 as you approach your full dose. Dramatic results in the first two to four weeks are not typical and not necessary for long-term success.

Will I regain the weight if I stop taking semaglutide? The STEP 1 extension study found that participants regained approximately two-thirds of their lost weight in the year after stopping medication. Maintaining weight loss after discontinuing a GLP-1 medication requires sustained dietary and lifestyle changes. Speak with your provider about long-term treatment planning before stopping.

Is there a minimum amount of weight I should expect to lose? Clinically, a 5% reduction in body weight is considered a meaningful threshold for health benefits, including improvements in blood sugar, blood pressure, and cholesterol. In the STEP 1 trial, 86.4% of participants achieved at least 5% weight loss. However, individual results vary and cannot be guaranteed.

Does it matter how much I weigh to begin with? Starting weight influences absolute weight loss but not necessarily the percentage achieved. All adults who qualify medically (typically BMI 30+, or BMI 27+ with a weight-related health condition) are candidates for evaluation by a licensed provider.

What if my progress is slower than expected? Many factors affect individual response. If your progress is slower than expected, speak with your provider. They may review your dose, assess adherence, evaluate dietary and activity patterns, and identify any underlying factors that could be addressed.

Can everyone use semaglutide for weight loss? No. Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or certain other conditions. A licensed healthcare provider evaluates your full medical history before prescribing.

---

Ready to Explore Your Options?

If you are curious whether a medically supervised GLP-1 program is right for you, Prescriva connects you with licensed healthcare providers who can evaluate your individual health profile and discuss whether treatment is appropriate.

[Check your eligibility today](https://prescriva.com/start)

---

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/). doi:10.1056/NEJMoa2032183

1. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat Med.* 2022;28(10):2083-2091. [PMID: 36216945](https://pubmed.ncbi.nlm.nih.gov/36216945/). doi:10.1038/s41591-022-02026-4

1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. *Diabetes Obes Metab.* 2022;24(8):1553-1564. [PMID: 35297580](https://pubmed.ncbi.nlm.nih.gov/35297580/). doi:10.1111/dom.14725

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded semaglutide is not an FDA-approved medication. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus). Clinical trial data cited in this article refers to FDA-approved semaglutide formulations and may not reflect outcomes from compounded semaglutide.

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Prescriva is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.